Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates
Portfolio Pulse from
Recursion Pharmaceuticals (RXRX) reported a Q3 loss of $0.34 per share, missing the Zacks Consensus Estimate of a $0.33 loss. This is an improvement from the $0.43 loss per share a year ago.
November 07, 2024 | 1:15 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Recursion Pharmaceuticals reported a Q3 loss of $0.34 per share, slightly missing the consensus estimate of $0.33. However, this is an improvement from the previous year's $0.43 loss per share.
The company's Q3 loss per share was slightly worse than expected, which could negatively impact the stock price in the short term. However, the improvement from last year's loss may mitigate some negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100